AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pls find attached herewith intimation for loss of share certificates.04-04-2024
04-04-2024
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 29, 2024 for Aayush Agrawal, trustee Aayush Agrawal Trust30-03-2024
AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to SEBI (PIT) Regulations 2015 and Ajanta''s Code of Conduct for Insiders, the Trading Window shall remain closed from close of business hours of 29th March 2024 till 48 hours after the declaration of financial results for the quarter and year ended 31st March 2024.29-03-2024
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 22, 2024 for Ravi Agrawal, trustee Ravi Agrawal Trust22-03-2024
AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
PFA intimation w.r.t issue of duplicate share certificate.22-03-2024
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 21, 2024 for Aayush Agrawal, trustee Aayush Agrawal Trust22-03-2024
AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 21, 2024 for Ravi Agrawal, trustee Ravi Agrawal Trust22-03-2024
Buy Ajanta Pharma; target of Rs 2515: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 2515 in its research report dated January 31, 2024.07-02-2024
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
PFA herewith written transcript of earnings call conducted on 31st January 2024.05-02-2024
AJANTA PHARMA LTD. - 532331 - Participation In Investor Conference
Pls find enclosed schedule of participation in investor conference.02-02-2024